In this episode Joe is back as he is finally off call! We discuss one of the 'hip new' cholesterol medications called PCSK-9 inhibitors. More specifically, we look at the evidence around Evolocumab. We also give insight on to the patient population we think this medication would be appropriate for. Everyone is talking about the huge decrease in LDL cholesterol with this medication but as the surrogate sheriff reminds us 'patients don't care about surrogate endpoints'. We also discuss the other PSCK-9 inhibitor on Primary Care RAP (click here to subscribe). If you are wondering what piece of literature we reviewed because you want to do a little bit of your own investigation click on the link-

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.


Finally, if you like what you hear then sign up today for the podcast, directions on how to sign up can be found under the 'How To Sign Up' tab